By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Key Statistics

Email: n/a
Ownership: Public

Web Site: AmpliPhi Bio
Symbol: APHB


Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.

Company News
AmpliPhi Bio (APHB) Reports Second Quarter 2017 Financial Results And Business Highlights 8/15/2017 6:30:09 AM
AmpliPhi Bio (APHB) To Hold 2017 Second Quarter And Business Update Conference Call On August 14 8/7/2017 6:28:45 AM
AmpliPhi Bio (APHB) To Present At Bacteriophage Therapy Workshop Sponsored By The FDA And NIH 7/5/2017 6:10:15 AM
AmpliPhi Bio (APHB) Announces Presentation And Panel Participation At BIO International Convention 6/14/2017 7:00:53 AM
Effective Immediately: San Diego's AmpliPhi Bio (APHB) CEO Resigns, New Leader Named 6/1/2017 7:52:46 AM
AmpliPhi Bio (APHB) Reports First Quarter 2017 Financial Results And Provides Business Highlights 5/16/2017 7:50:07 AM
AmpliPhi Bio (APHB) Announces Closing Of Public Offering 5/11/2017 7:20:41 AM
AmpliPhi Bio (APHB) To Hold Business Update Conference Call On May 15 5/11/2017 6:57:46 AM
AmpliPhi Bio (APHB) Announces Pricing Of $10.4 Million Underwritten Public Offering Of Common Stock And Common Warrants 5/5/2017 6:20:45 AM
AmpliPhi Bio (APHB) Announces A New Strategic Emphasis On Personalized Therapies For Serious Or Life-Threatening Antibiotic-Resistant Infections 5/1/2017 6:19:15 AM